- Investors & Media
- Investors & Media
- Contact Us
Financial highlights of the 2015 second quarter included:
Total revenues of $19.2 million compared with $15.8 million for the second quarter of 2014; Gross profit of $3.6 million compared with a gross loss of $0.10 million in the year-ago second quarter; Adjusted net loss of $1.8 million compared with an adjusted net loss of $7.4 in the year-ago second quarter.
Kamada management will host an investment community conference call on Thursday, July 30, 2015 at 8:30 a.m. Eastern time to discuss these results and answer questions.
The Company expects to report complete financial results for the three and six months ended June 30, 2015 on July 30th. Information regarding the conference call with investors will be provided in a separate notification in the coming weeks.
Demonstrated profound safety of multiple intravenous doses of AAT therapy for treatment of newly diagnosed type 1 diabetes while maintaining glycemic control and less of a decrease in C-Peptide levelsץ
Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016.
Additional analyses demonstrate that inhaled AAT is able to change the nature of exacerbations to events with fewer symptoms (statistically significant), a change that correlates with the benefit seen in lung function.
Data highlighted in panel discussion with renowned pulmonology experts who specialize in treating patients with alpha-1 antitrypsin deficiency will serve as basis for MAA submission in Europe
Introduces 2015 Revenue Guidance
Conference call begins today at 8:30 a.m. Eastern time
Dial in numbers for the conference call: USA: 186-629-702-42 or 188-854-512-12 Israel: 03-9180600 Conference Code: 76224# NESS ZIONA, Israel (May 8, 2015) – Kamada Ltd. (NASDAQ and TASE: KMDA), a…
Dial in numbers for the conference call: USA: 186-629-702-42 or 188-854-512-12 Israel: 03-9180600 Conference Code: 76224# NESS ZIONA, Israel (May 8, 2015) – Kamada Ltd. (NASDAQ and TASE: KMD), a…
Panel of Leading Pulmonologists to Discuss Potential New Treatment Option for Alpha-1 Antitrypsin Deficiency Patients